Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Leases (2019 - 2025)

Crinetics Pharmaceuticals has reported Operating Leases over the past 7 years, most recently at $48.5 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 8.91% year-over-year to $48.5 million; the TTM value through Dec 2025 reached $48.5 million, up 8.91%, while the annual FY2025 figure was $48.5 million, 8.91% up from the prior year.
  • Operating Leases for Q4 2025 was $48.5 million at Crinetics Pharmaceuticals, down from $49.1 million in the prior quarter.
  • Over five years, Operating Leases peaked at $49.1 million in Q3 2025 and troughed at $1.5 million in Q2 2023.
  • A 5-year average of $24.5 million and a median of $23.6 million in 2021 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: tumbled 43.24% in 2023 and later surged 3050.62% in 2024.
  • Year by year, Operating Leases stood at $3.1 million in 2021, then crashed by 34.16% to $2.0 million in 2022, then surged by 2249.56% to $47.6 million in 2023, then decreased by 6.28% to $44.6 million in 2024, then increased by 8.91% to $48.5 million in 2025.
  • Business Quant data shows Operating Leases for CRNX at $48.5 million in Q4 2025, $49.1 million in Q3 2025, and $43.3 million in Q2 2025.